Avalo Therapeutics, Inc.
NASDAQ:AVTX
Overview | Financials
Company Name | Avalo Therapeutics, Inc. |
Symbol | AVTX |
Currency | USD |
Price | 8.81 |
Market Cap | 92,184,316 |
Dividend Yield | 0% |
52-week-range | 3.95 - 34.46 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Garry A. Neil M.D. |
Website | https://www.avalotx.com |
An error occurred while fetching data.
About Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD